Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens

Journal of the International Association of Providers of AIDS Care

Volumn 14, Issue 5, 2015, Pages 455-462

  Parkes Ratanshi, Rosalind ^a,b,f   Katende, David ^a   Levin, Jonathan ^a,c   Wakeham, Katie ^a,b,d   Heiner, Grosskurth ^a,e   Kamali, Anatoli ^a   Lalloo, David G ^b,f  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF YORK   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Infectious Diseases Institute   (Uganda)

Author keywords

Africa; anemia; ART; hemoglobin; tenofovir; Uganda; zidovudine

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FLUCONAZOLE; HEMOGLOBIN; LAMIVUDINE; NEVIRAPINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UGANDA; UGANDAN; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; METABOLISM; VIROLOGY;

ADULT; ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TENOFOVIR; UGANDA; ZIDOVUDINE;

EID: 84941953722     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957414557264     Document Type: Article

References (29)

1. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999; 13 (8): 943-950.
2. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW,. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998; 91 (1): 301-308.
3. Mugisha JO, Shafer LA, Van der Paal L, et al. Anaemia in a rural Ugandan HIV cohort: prevalence at enrolment, incidence, diagnosis and associated factors. Trop Med Int Health. 2008; 13 (6): 788-794.
4. Sullivan P,. Associations of anemia, treatments for anemia, and survival in patients with human immunodeficiency virus infection. J Infect Dis. 2002; 185 (suppl 2): S138-S142.
5. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Womens Interagency HIV Study. J Acquir Immune Defic Syndr. 2001; 26 (1): 28-35.
6. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Vlahov D,. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis. 2002; 34 (2): 260-266.
7. Centers for Disease Control and Prevention. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents [Internet]. MMWR. 2009: 1-198.
8. Moore RD, Forney D,. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 29 (1): 54-57.
9. Semba RD, Shah N, Klein RS, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDS. 2001; 15 (9): 473-80.
10. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989; 262 (17): 2405-2010.
11. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317 (4): 192-197.
12. Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F,. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2007; 8 (8): 483-490.
13. Moyle G, Sawyer W, Law M, Amin J, Hill A,. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther. 2004; 26 (1): 92-97.
14. WHO. Antiretroviral therapy for HIV infection for adults and adolescents; 2010. Web site. http://wwwwhoint/3by5/publications/briefs/oms09arvguidelinespdf. Accessed June 21, 2012.
15. Gallant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006; 354 (23): 251-260.
16. Gallant J, Stazeweski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-year randomized trial. J Am Med Assoc. 2004; 292 (2): 191-201.
17. World Health Organization. Consolidated Guidelines on General HIV Care and the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2013.
18. Ssali F, Stohr W, Munderi P, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther. 2006; 11 (6): 741-749.
19. Moh R, Danel C, Sorho S, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote dIvoire. Antivir Ther. 2005; 10 (5): 615-624.
20. Zhou J, Jaquet A, Bissagnene E, et al. Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. J Int AIDS Soc. 2012; 15 (1): 5.
21. Huffam SE, Srasuebkul P, Zhou J, et al. Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med. 2007; 8 (7): 465-471.
22. Forna F, Moore D, Mermin J, et al. Hematologic changes associated with zidovudine following single-drug substitution from stavudine in a home-based AIDS care program in rural Uganda. J Int Assoc Physicians AIDS Care (Chic). 2009; 8 (2): 128-138.
23. Omoregie R, Omokaro EU, Palmer O, et al. Prevalence of anaemia among HIV-infected patients in Benin City, Nigeria. Tanzan J Health Res. 2009; 11 (1): 1-4.
24. Owiredu WK, Quaye L, Amidu N, Addai-Mensah O,. Prevalence of anaemia and immunological markers among ghanaian HAART-naive HIV-patients and those on HAART. Afr Health Sci. 2011; 11 (1): 2-15.
25. Kiragga AN, Castelnuovo B, Nakanjako D, Manabe YC,. Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc. 2010; 13: 42.
26. Parkes-Ratanshi R, Wakeham K, Levin J, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011; 11 (12): 933-941.
27. Royston P, Ambler G, Sauerbrei W,. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999; 28 (5): 964-974.
28. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010; 375 (9709): 123-131.
29. Nacoulma EW, Some Y, Tieno H, et al. Haematological parameters evolution during the antiretroviral therapy of HIV-infected patients in Burkina-Faso [in French]. Bull Soc Pathol Exot. 2007; 100 (4): 271-274.